HYDERABAD: Less than six months after it rolled out wearable migraine management device Nerivio in the Indian market, Dr Reddy’s Laboratories has now rolled out the drug-free, non-invasive device in the European market.
The company has launched Nerivio in Germany to start with through its step-down subsidiary betapharm, marking its foray into digital therapeutics in Europe.
It plans to also introduce Nerivio in Spain and the UK in the coming months, Dr Reddy’s said on Wednesday.
The Hyderabad-based pharma major has an exclusive agreement with digital therapeutics player Theranica for marketing and distributing Nerivio in multiple markets.
The prescription-based device, which can be worn on the upper arm, is meant for treating adults and adolescents aged 12 years and above suffering from migraine with or without aura.
The device uses the Remote Electrical Neuromodulation (REN) mechanism to activate conditioned pain modulation by stimulating nerve endings. This initiates a natural pain-relieving process in the brainstem, causing a global effect of pain inhibition that affects the original source of migraine pain in the head.
Each device has in-built 18 treatment sessions of 45 minutes each and can be used within 60 minutes of onset of headache for acute treatment or every alternate day for prevention of migraine.
Dr Reddy’s CEO for branded markets (India & emerging markets) MV Ramana said the device has received positive feedback from neurologists in India and has shown promising results in providing relief to migraine patients, helping address their unmet clinical needs and reducing their pill burden.
The device is approved by the United States Food & Drug Administration (USFDA) and holds the CE-mark certification in Europe.
It has been showcased at events such as the DGN Kongress and the European Headache Congress in 2023, and will also be presented at the Neurological Association of South Africa annual congress on April 17, this year.
Nerivio will also be showcased at the International Headache Society 2024 iHEAD meeting in Berlin, Germany, in May 2024.
The company has launched Nerivio in Germany to start with through its step-down subsidiary betapharm, marking its foray into digital therapeutics in Europe.
It plans to also introduce Nerivio in Spain and the UK in the coming months, Dr Reddy’s said on Wednesday.
The Hyderabad-based pharma major has an exclusive agreement with digital therapeutics player Theranica for marketing and distributing Nerivio in multiple markets.
The prescription-based device, which can be worn on the upper arm, is meant for treating adults and adolescents aged 12 years and above suffering from migraine with or without aura.
The device uses the Remote Electrical Neuromodulation (REN) mechanism to activate conditioned pain modulation by stimulating nerve endings. This initiates a natural pain-relieving process in the brainstem, causing a global effect of pain inhibition that affects the original source of migraine pain in the head.
Each device has in-built 18 treatment sessions of 45 minutes each and can be used within 60 minutes of onset of headache for acute treatment or every alternate day for prevention of migraine.
Dr Reddy’s CEO for branded markets (India & emerging markets) MV Ramana said the device has received positive feedback from neurologists in India and has shown promising results in providing relief to migraine patients, helping address their unmet clinical needs and reducing their pill burden.
The device is approved by the United States Food & Drug Administration (USFDA) and holds the CE-mark certification in Europe.
It has been showcased at events such as the DGN Kongress and the European Headache Congress in 2023, and will also be presented at the Neurological Association of South Africa annual congress on April 17, this year.
Nerivio will also be showcased at the International Headache Society 2024 iHEAD meeting in Berlin, Germany, in May 2024.
